CHMP recommends approval of Cablivi(TM) (caplacizumab)
First therapeutic to receive positive CHMP opinion for treatment of a rare blood disorder called acquired thrombotic thrombocytopenic purpura
The European Me...
Insights into the latest developments in CDMO services and manufacturing.
Continue readingExpert perspectives on the evolving needs of injectable therapies and packaging.
Continue readingExploring the latest developments in inhalation technologies, respiratory delivery and sustainability
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement